Alpha Centric Advisors LLC Uro Gen Pharma Ltd. Transaction History

Alpha Centric Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	SELL	$13.81 - $19.33 $153,318 - $214,601	-11,102 Reduced 7.16%	143,898 $2.16 Million
Q4 2023 Feb 14, 2024	SELL	$10.87 - $15.93 $108,699 - $159,300	-10,000 Reduced 6.06%	155,000 $2.33 Million
Q3 2023 Nov 13, 2023	BUY	$8.84 - $22.64 $110,500 - $283,000	12,500 Added 8.2%	165,000 $2.31 Million
Q2 2023 Aug 08, 2023	BUY	$8.75 - $14.29 $1.33 Million - $2.18 Million	152,500 New	152,500 $1.58 Million

130

35.9M

22K

93.8K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $260M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.